Multiple Doses of AT-1501-A201 in Adults With ALS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04322149 |
Recruitment Status :
Completed
First Posted : March 26, 2020
Results First Posted : June 28, 2023
Last Update Posted : June 28, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites.
Participants will be enrolled into one of four ascending doses.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Amyotrophic Lateral Sclerosis | Drug: AT-1501 | Phase 2 |
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40L. Approximately 54 adults with ALS will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites.
Four ascending doses of AT-1501 will be administered as an IV infusion to sequentially enrolling cohorts. Each participant will receive 6 bi-weekly (every other week) infusions of AT-1501 over an 11-week period.
The study is estimated to take 19 weeks for participants.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 54 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS |
Actual Study Start Date : | October 16, 2020 |
Actual Primary Completion Date : | March 24, 2022 |
Actual Study Completion Date : | March 24, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: AT-1501
4 sequential dose cohorts
|
Drug: AT-1501
AT-1501 monoclonal antibody targeting CD40L given as an IV infusion |
- Safety and Tolerability [ Time Frame: Up to 18 Weeks ]Incidence of adverse events (AEs) reported as number of participants with at least one TEAE (Treatment Emergent Adverse Event) and at least one SAE (Serious Adverse Event).
- Safety and Tolerability [ Time Frame: Up to 18 Weeks ]Incidence of adverse events (AEs) reported as number of TEAEs (Treatment Emergent Adverse Events) having occurred.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ALS diagnosed as possible, laboratory supported probable, probable, or definite as defined by revised El Escorial criteria
- ALS Functional Rating Scale - Revised (ALSFRS-R) Aggregate score of 37 or greater
- No more than 24 months from diagnosis
Exclusion Criteria:
- Any other central or peripheral nervous system disease that may interfere with the evaluation of ALS or its progression
- Presence of a tracheostomy, or use of permanent assistive ventilation (ventilatory support for 23 hours per day or more)
- History of malignancy within the previous 5 years, except for localized non-melanoma skin cancers
-
Abnormal function of the immune system resulting from:
- Clinical conditions affecting the immune system (e.g. HIV infection, agammaglobulinemia),
- Systemic administration of corticosteroids (PO/IV/IM) at a dose equivalent to 20 mg/day of prednisone for more than 14 consecutive days within 90 days prior to screening,
- Administration of anti-neoplastic and/or immunomodulating agents (e.g. Tumor necrosis factor alpha (TNF α) antagonists or anti-B cell antibodies) or radiotherapy within 1 year prior to screening.
- Recipient of Stem Cell or Gene Therapy
- Positive test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV.
- History of deep venous thrombosis or pulmonary embolism
- History of active substance abuse within the past 2 years
- History of stroke, poorly controlled or significant cardiovascular disease, diabetes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04322149
United States, Arizona | |
Barrows Neurological Institute | |
Phoenix, Arizona, United States, 85013 | |
United States, California | |
University of California Irvine | |
Orange, California, United States, 92868 | |
California Pacific Medical Center | |
San Francisco, California, United States, 94109 | |
United States, Georgia | |
Augusta University | |
Augusta, Georgia, United States, 30912 | |
United States, Indiana | |
University of Indiana | |
Indianapolis, Indiana, United States, 46202 | |
United States, Kansas | |
The University of Kansas Medical Center | |
Kansas City, Kansas, United States, 66160 | |
United States, Maryland | |
Johns Hopkins University Medical Center | |
Baltimore, Maryland, United States, 21287 | |
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
United States, New York | |
Hospital for Special Surgery (HSS) | |
New York, New York, United States, 10021 | |
United States, Oregon | |
Providence Brain & Spine Institute | |
Portland, Oregon, United States, 97213 | |
United States, Texas | |
Texas Neurology, P.A. | |
Dallas, Texas, United States, 75206 | |
Houston Methodist Neurological Institute | |
Houston, Texas, United States, 77030 | |
Canada | |
Montreal Neurological Institute and Hospital | |
Montreal, Canada, H3A 2B4 |
Study Chair: | Jeff Bornstein, MD | Eledon Pharmaceuticals |
Documents provided by Eledon Pharmaceuticals ( Anelixis Therapeutics, LLC ):
Responsible Party: | Anelixis Therapeutics, LLC |
ClinicalTrials.gov Identifier: | NCT04322149 |
Other Study ID Numbers: |
AT-1501-A201 |
First Posted: | March 26, 2020 Key Record Dates |
Results First Posted: | June 28, 2023 |
Last Update Posted: | June 28, 2023 |
Last Verified: | June 2023 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
ALS Lou Gehrig's Disease motor neuron disease motor neuron degeneration |
AT-1501 humanized blocking antibody to CD40LG CD40L inhibitor monoclonal antibody |
Motor Neuron Disease Amyotrophic Lateral Sclerosis Neurodegenerative Diseases Nervous System Diseases Neuromuscular Diseases |
Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases |